SLC34A2 (solute carrier family 34 member 2)

2010-12-01  

Identity

HGNC
LOCATION
4p15.2
LOCUSID
ALIAS
NAPI-3B,NAPI-IIb,NPTIIb,PULAM
FUSION GENES

Other Information

Locus ID:

NCBI: 10568
MIM: 604217
HGNC: 11020
Ensembl: ENSG00000157765

Variants:

dbSNP: 10568
ClinVar: 10568
TCGA: ENSG00000157765
COSMIC: SLC34A2

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000157765ENST00000382051O95436
ENSG00000157765ENST00000503434O95436
ENSG00000157765ENST00000504570O95436
ENSG00000157765ENST00000507530D6RBC0
ENSG00000157765ENST00000513204D6RA94
ENSG00000157765ENST00000645788O95436

Expression (GTEx)

0
50
100
150
200
250
300
350

Pathways

PathwaySourceExternal ID
Mineral absorptionKEGGko04978
Mineral absorptionKEGGhsa04978
Metabolism of proteinsREACTOMER-HSA-392499
Transmembrane transport of small moleculesREACTOMER-HSA-382551
SLC-mediated transmembrane transportREACTOMER-HSA-425407
Transport of inorganic cations/anions and amino acids/oligopeptidesREACTOMER-HSA-425393
Sodium-coupled phosphate cotransportersREACTOMER-HSA-427652
Type II Na+/Pi cotransportersREACTOMER-HSA-427589
Surfactant metabolismREACTOMER-HSA-5683826

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
387204722024SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma.1
387204722024SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma.1
372591442023New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review.0
372591442023New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review.0
354437212022Impaired phosphate transport in SLC34A2 variants in patients with pulmonary alveolar microlithiasis.3
354437212022Impaired phosphate transport in SLC34A2 variants in patients with pulmonary alveolar microlithiasis.3
349445222021Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases.4
349445222021Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases.4
315409802020Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.14
318315822020Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis.11
320059742020SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.21
315409802020Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.14
318315822020Eight novel variants in the SLC34A2 gene in pulmonary alveolar microlithiasis.11
320059742020SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.21
300380602019The SLC34A2-ROS-HIF-1-induced up-regulation of EZH2 expression promotes proliferation and chemo-resistance to apoptosis in colorectal cancer.14

Citation

Dessen P

SLC34A2 (solute carrier family 34 member 2)

Atlas Genet Cytogenet Oncol Haematol. 2010-12-01

Online version: http://atlasgeneticsoncology.org/gene/51842/case-report-explorer/meetings/teaching-explorer/